Corresponding Author: Kim L. Bennell, PhD, Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, The University of Melbourne, 161 Barry St, Carlton, VIC 3010, Australia (k.bennell@unimelb.edu.au).
Accepted for Publication: October 12, 2021.
Author Contributions: Drs Bennell and Kasza had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Bennell and Paterson are co–first authors and contributed equally to the article.
Concept and design: Bennell, Paterson, Kasza, Y. Wang, Cicuttini, Buchbinder, Harris, Connell, Linklater, Hunter.
Acquisition, analysis, or interpretation of data: Bennell, Metcalf, Duong, Eyles, Kasza, Y. Wang, Cicuttini, Buchbinder, Forbes, Yu, Connell, Linklater, B. Wang, Oo, Hunter.
Drafting of the manuscript: Bennell, Paterson, Metcalf, Kasza, Linklater.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Metcalf, Kasza, Forbes.
Obtained funding: Bennell, Y. Wang, Buchbinder, Hunter.
Administrative, technical, or material support: Paterson, Metcalf, Duong, Eyles, Cicuttini, Harris, Yu, Linklater, B. Wang.
Supervision: Bennell, Paterson, Eyles, Y. Wang, Cicuttini, Connell, Linklater, Hunter.
Conflict of Interest Disclosures: Dr Bennell reported receiving personal fees from Wolters Kluwer for production of UpToDate knee OA clinical guidelines. Dr Paterson reported receiving grants from the Australian National Health and Medical Research Council (NHMRC) outside the submitted work. Dr Buchbinder report receiving funding from the NHMRC outside the submitted work. Dr Yu reported receiving royalties from Wolters Kluwer for contributions to UpToDate. Mr Connell reported providing PRP injections in clinical practice (Imaging @ Olympic Park). Dr Linklater reported providing PRP injections in clinical practice (Castlereagh Imaging). Dr Hunter reported receiving personal fees for scientific advisory board membership from Biobone, Novartis, Tissuegene, Pfizer, and Lilly. No other disclosures were reported.
Funding/Support: The study was funded by NHMRC project grant 1106274. Regen Lab SA provided the commercial kits free of charge.
Role of the Funder/Sponsor: The NHMRC, the University of Melbourne, and Regen Lab SA had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Data Sharing Statement: See Supplement 4.
Additional Contributions: We thank Paris Arlegui (Imaging @ Olympic Park), for administrative assistance; Jade McTernan, BSc, Naomi Haverty, BSN, and Tom Entwisle, MBBS (all from Imaging @ Olympic Park), and Annie Phillips, DipAppSci, Jennie Noakes, BMed, and Danielle Pryke, GDip (all from Castlereagh Imaging), for assisting with administration of PRP injections; and Sarah Robbins, BPhty (University of Sydney), for assisting with project management. Their roles were supported through the NHMRC research grant.
1.GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
Lancet. 2018;392(10159):1789-1858. doi:
10.1016/S0140-6736(18)32279-7PubMedGoogle ScholarCrossref 3.Kolasinski
SL , Neogi
T , Hochberg
MC ,
et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee.
Arthritis Rheumatol. 2020;72(2):220-233. doi:
10.1002/art.41142PubMedGoogle ScholarCrossref 5.Werner
BC , Cancienne
JM , Browning
R , Verma
NN , Cole
BJ . An analysis of current treatment trends in platelet-rich plasma therapy in the Medicare database.
Orthop J Sports Med. 2020;8(2):2325967119900811. doi:
10.1177/2325967119900811PubMedGoogle Scholar 6.Hohmann
E , Tetsworth
K , Glatt
V . Is platelet-rich plasma effective for the treatment of knee osteoarthritis? a systematic review and meta-analysis of level 1 and 2 randomized controlled trials.
Eur J Orthop Surg Traumatol. 2020;30(6):955-967. doi:
10.1007/s00590-020-02623-4PubMedGoogle ScholarCrossref 7.Shen
L , Yuan
T , Chen
S , Xie
X , Zhang
C . The temporal effect of platelet-rich plasma on pain and physical function in the treatment of knee osteoarthritis: systematic review and meta-analysis of randomized controlled trials.
J Orthop Surg Res. 2017;12(1):16. doi:
10.1186/s13018-017-0521-3PubMedGoogle ScholarCrossref 8.Patel
S , Dhillon
MS , Aggarwal
S , Marwaha
N , Jain
A . Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial.
Am J Sports Med. 2013;41(2):356-364. doi:
10.1177/0363546512471299PubMedGoogle ScholarCrossref 9.Buendía-López
D , Medina-Quirós
M , Fernández-Villacañas Marín
MA . Clinical and radiographic comparison of a single LP-PRP injection, a single hyaluronic acid injection and daily NSAID administration with a 52-week follow-up: a randomized controlled trial.
J Orthop Traumatol. 2018;19(1):3. doi:
10.1186/s10195-018-0501-3PubMedGoogle ScholarCrossref 10.Elik
H , Doğu
B , Yılmaz
F , Begoğlu
FA , Kuran
B . The efficiency of platelet-rich plasma treatment in patients with knee osteoarthritis.
J Back Musculoskelet Rehabil. 2020;33(1):127-138. doi:
10.3233/BMR-181374PubMedGoogle ScholarCrossref 11.Ahmad
HS , Farrag
SE , Okasha
AE ,
et al. Clinical outcomes are associated with changes in ultrasonographic structural appearance after platelet-rich plasma treatment for knee osteoarthritis.
Int J Rheum Dis. 2018;21(5):960-966. doi:
10.1111/1756-185X.13315PubMedGoogle ScholarCrossref 12.Paterson
KL , Hunter
DJ , Metcalf
BR ,
et al. Efficacy of intra-articular injections of platelet-rich plasma as a symptom- and disease-modifying treatment for knee osteoarthritis—the RESTORE trial protocol.
BMC Musculoskelet Disord. 2018;19(1):272. doi:
10.1186/s12891-018-2205-5PubMedGoogle ScholarCrossref 13.Murray
IR , Geeslin
AG , Goudie
EB , Petrigliano
FA , LaPrade
RF . Minimum information for studies evaluating biologics in orthopaedics (MIBO): platelet-rich plasma and mesenchymal stem cells.
J Bone Joint Surg Am. 2017;99(10):809-819. doi:
10.2106/JBJS.16.00793PubMedGoogle ScholarCrossref 17.RegenBCT Tube Performance. Version 3. Regen Lab; February 25, 2015.
19.Bellamy
N , Carette
S , Ford
PM ,
et al. Osteoarthritis antirheumatic drug trials, II: tables for calculating sample size for clinical trials.
J Rheumatol. 1992;19(3):444-450.
PubMedGoogle Scholar 23.ten Klooster
PM , Drossaers-Bakker
KW , Taal
E , van de Laar
MA . Patient-Perceived Satisfactory Improvement (PPSI): interpreting meaningful change in pain from the patient’s perspective.
Pain. 2006;121(1-2):151-157. doi:
10.1016/j.pain.2005.12.021PubMedGoogle Scholar 26.Bennell
KL , Bowles
KA , Payne
C ,
et al. Lateral wedge insoles for medial knee osteoarthritis: 12 month randomised controlled trial.
BMJ. 2011;342(7808):d2912. doi:
10.1136/bmj.d2912PubMedGoogle Scholar 27.Carpenter
JG , Kenward
MG .
Multiple Imputation and Its Application. John Wiley & Sons Ltd; 2013. doi:
10.1002/9781119942283 29.Royston
P , Sauerbrei
W . A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials.
Stat Med. 2004;23(16):2509-2525. doi:
10.1002/sim.1815PubMedGoogle ScholarCrossref 30.Hong
M , Cheng
C , Sun
X ,
et al. Efficacy and safety of intra-articular platelet-rich plasma in osteoarthritis knee: a systematic review and meta-analysis.
Biomed Res Int. 2021;2021:2191926. doi:
10.1155/2021/2191926PubMedGoogle Scholar 33.Belk
JW , Kraeutler
MJ , Houck
DA , Goodrich
JA , Dragoo
JL , McCarty
EC . Platelet-rich plasma versus hyaluronic acid for knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials.
Am J Sports Med. 2021;49(1):249-260. doi:
10.1177/0363546520909397PubMedGoogle ScholarCrossref